Directorate Change

Dechra Pharmaceuticals PLC

16 June 2023

 

16 June 2023

Dechra^® Pharmaceuticals PLC

("Dechra" or "the Company") 

Directorate Change

Further to the announcement made on 20 December 2022 which stated that Ishbel Macpherson intended to step down as a Non-Executive Director of the Company on 30 June 2023, she has informed the Board that she has decided to tender her resignation and step down from the Board on 22 June 2023.

Alison Platt, Chair, Dechra said:

Ishbel's contribution to the Board over the last ten years has been outstanding and we wish her well in her future endeavours. We would like to thank her for the additional time spent on the Board to enable Dechra to appoint a replacement Non-Executive Director and Remuneration Committee Chair.

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office:  [phone]
e-mail: [e-mail]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail: [e-mail]	Mobile: [phone] Office:  [phone]

About Dechra

Dechra is  a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide.  Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

END